International Workshop on Clinical Pharmacology of HIV & Hepatitis Therapy 2016

Pharmacokinetic, Safety and Efficacy of Darunavir/Ritonavir in HIV+ Pregnant Women - Dr. Minh Patrick Le

Slideset

HIV

Viral Hepatitis and Liver Disease

Raltegravir (RAL) Pharmacokinetics (PK) and Safety in HIV-1 Exposed Neonates at High Risk of Infection (IMPAACT P1110) - Dr. Diana Clarke

Slideset

HIV

Viral Hepatitis and Liver Disease

Timing of the postpartum curve in pharmacokinetic studies in pregnancy should not be too early - Angela Colbers, PhD

Slideset

HIV

Viral Hepatitis and Liver Disease

Other Viruses: using Wolbachia to interrupt transmission of viral infections such as Dengue, Chikungunya and Zika - Steven Kern, PhD

Slideset

HIV

Viral Hepatitis and Liver Disease

Effect of Renal Impairment on Drugs Primarily Eliminated by Metabolism or Biliary Excretion: Review of Data from HCV DAA Drugs and Literature - Dr. Tushar Garimella

Slideset

HIV

Viral Hepatitis and Liver Disease

Effect of daclatasvir/asunaprevir/beclabuvir in fixed-dose combination on the pharmacokinetics of CYP450/transporter substrates in healthy subjects- Dr. Tushar Garimella

Slideset

HIV

Viral Hepatitis and Liver Disease

The FDA Perspective on Hepatitis C Drug Resistance - Patrick Harrington, PHD

Slideset

HIV

Viral Hepatitis and Liver Disease

Cumulative tenofovir exposure is associated with decreased BMD in young and old HIV-infected adults on tenofovir based regimens - Sharon Seifert, PhramD

Slideset

HIV

Viral Hepatitis and Liver Disease

Evaluation of Drug-Drug Interaction Between Sofosbuvir/Velpatasvir and Rifaximin in HCV-Infected Subjects with Moderate Hepatic Impairment - Erik Mogalian

Slideset

HIV

Viral Hepatitis and Liver Disease

Intracellular Metabolism of Tenofovir Alafenamide in Cervical and Vaginal Epithelial Cells - Mackenzie Cottrell, PharmD

Slideset

HIV

Viral Hepatitis and Liver Disease

Pharmacogenetics of Efavirenz Discontinuation for Central Nervous System Symptoms at a Southeastern United States Clinic May Differ by Race - Paul Leger, MD, MPH

Slideset

HIV

Viral Hepatitis and Liver Disease

Virologic and Immunologic Responses to Raltegravir and Dolutegravir in GALT of HIV+ Men and Women - Michael Weber, PharmD

Slideset

HIV

Viral Hepatitis and Liver Disease

Efficacy of once-weekly MK-8591 in SIV infected rhesus macaques - Dr. Matthew Rizk

Slideset

HIV

Viral Hepatitis and Liver Disease

In silico pharmacokinetic/pharmacodynamic simulation of long acting tenofovir injectable formulation for pre exposure prophylaxis strategies - Dr. Paul Curley

Slideset

HIV

Viral Hepatitis and Liver Disease

Looking Backwards: Hormonal Contraception and ART - Kimberly Scarsi, PharmD, MS, FCCP

Slideset

HIV

Viral Hepatitis and Liver Disease

Will we see the Back of DDIs? - Catia Marzolini, PharmD, PhD

Slideset

HIV

Viral Hepatitis and Liver Disease

Pharmacogenetics - Back to reality - Andrew Owen, BSS, MSC, PhD, FSB

Slideset

HIV

Viral Hepatitis and Liver Disease

The ‘Back Side’ of Compartments - Saye Khoo, MD, PhD

Slideset

HIV

Viral Hepatitis and Liver Disease

Back-terial co-infections - Mohammed Lamorde, FRCP, PhD

Slideset

HIV

Viral Hepatitis and Liver Disease

Specific Complex Interactions (mechanic presentation) - David Burger, PharmD, PhD

Slideset

HIV

Viral Hepatitis and Liver Disease

PBPK/PD Modeling and Simulations to Guide Dose Recommendation of Amlodipine after Co-administration with Viekirax or Viekira Pak - Dwaipayan Mukherjee, PhD

Slideset

HIV

Viral Hepatitis and Liver Disease

Backing up clinical data with modelling - Marco Siccardi, PhD

Slideset

HIV

Viral Hepatitis and Liver Disease

Effects of Sofosbuvir/Ribavirin Treatment and ITPA Phenotype on Endogenous Purines - Dr. Leah Jimmerson

Slideset

HIV

Viral Hepatitis and Liver Disease

Rifampin (RIF) Decreases Cabotegravir (CAB) Exposure following Oral Coadministration - Dr. Susan Ford

Slideset

HIV

Viral Hepatitis and Liver Disease

Increased Tenofovir Diphosphate in Red Blood Cells, but Not Tenofovir in Plasma, with Sofosbuvir and Ribavirin - Dr. Christine MacBrayne

Slideset

HIV

Viral Hepatitis and Liver Disease

MK-3682, a HCV NS5B Inhibitor with a Broad Spectrum of HCV Genotypic Activity, Demonstrates Potent Antiviral Activity in Genotypes -1,-2, and -3 HCV-Infected Patients - Dr. Nancy Kim

Slideset

HIV

Viral Hepatitis and Liver Disease

Pharmacokinetics of Darunavir, Ombitasvir, Paritaprevir, Ritonavir, Dasabuvir and Ribavirin in Adults Infected with Hepatitis C Virus (HCV) Genotype (GT) 1 and Human Immunodeficiency Virus Type 1 (HIV-1) - Dr. Jennifer King

Slideset

HIV

Viral Hepatitis and Liver Disease

Physiologically-based simulation of daclatasvir pharmacokinetics with antiretroviral inducers and inhibitors of cytochrome P450 and drug transporters - Dr. Timothy Eley

Slideset

HIV

Viral Hepatitis and Liver Disease

Pharmacokinetics of Dolutegravir after Switching to Abacavir/Dolutegravir/Lamivudine from an Efavirenz Based Regimen: A PK Substudy from Striiving - Dr. Jeff de Wet

Slideset

HIV

Viral Hepatitis and Liver Disease

A Clinically Meaningful Drug-Drug Interaction Observed Between ZepatierTM (Grazoprevir/Elbasvir) and Stribild® HIV Fixed-Dose Combination in Healthy Subjects - Dr. Hwa-Ping Feng

Slideset

HIV

Viral Hepatitis and Liver Disease

Evaluation of Pan Genotypic HCV NS3/4A Protease Inhibitor GS-9857 as the Object of Transporter and Cytochrome P450-Mediated Drug-Drug Interactions - Dr. Brian Kirby

International Workshop on Clinical Pharmacology of HIV & Hepatitis Therapy 2016

Pharmacokinetic, Safety and Efficacy of Darunavir/Ritonavir in HIV+ Pregnant Women - Dr. Minh Patrick Le

Raltegravir (RAL) Pharmacokinetics (PK) and Safety in HIV-1 Exposed Neonates at High Risk of Infection (IMPAACT P1110) - Dr. Diana Clarke

Timing of the postpartum curve in pharmacokinetic studies in pregnancy should not be too early - Angela Colbers, PhD

Other Viruses: using Wolbachia to interrupt transmission of viral infections such as Dengue, Chikungunya and Zika - Steven Kern, PhD

Effect of Renal Impairment on Drugs Primarily Eliminated by Metabolism or Biliary Excretion: Review of Data from HCV DAA Drugs and Literature - Dr. Tushar Garimella

Effect of daclatasvir/asunaprevir/beclabuvir in fixed-dose combination on the pharmacokinetics of CYP450/transporter substrates in healthy subjects- Dr. Tushar Garimella

The FDA Perspective on Hepatitis C Drug Resistance - Patrick Harrington, PHD

Cumulative tenofovir exposure is associated with decreased BMD in young and old HIV-infected adults on tenofovir based regimens - Sharon Seifert, PhramD

Evaluation of Drug-Drug Interaction Between Sofosbuvir/Velpatasvir and Rifaximin in HCV-Infected Subjects with Moderate Hepatic Impairment - Erik Mogalian

Intracellular Metabolism of Tenofovir Alafenamide in Cervical and Vaginal Epithelial Cells - Mackenzie Cottrell, PharmD

Pharmacogenetics of Efavirenz Discontinuation for Central Nervous System Symptoms at a Southeastern United States Clinic May Differ by Race - Paul Leger, MD, MPH

Virologic and Immunologic Responses to Raltegravir and Dolutegravir in GALT of HIV+ Men and Women - Michael Weber, PharmD

FDA Perspective on "oral run-in" phase - Dr. Yodit Belew

ViiV - Cabotegravir - Bill Spreen, PharmD

Target Concentrations - Angela Kashuba, PharmD

Janssen - Rilpivirine - Herta Crauwels, PhD

Efficacy of once-weekly MK-8591 in SIV infected rhesus macaques - Dr. Matthew Rizk

In silico pharmacokinetic/pharmacodynamic simulation of long acting tenofovir injectable formulation for pre exposure prophylaxis strategies - Dr. Paul Curley

Looking Backwards: Hormonal Contraception and ART - Kimberly Scarsi, PharmD, MS, FCCP

Will we see the Back of DDIs? - Catia Marzolini, PharmD, PhD

Pharmacogenetics - Back to reality - Andrew Owen, BSS, MSC, PhD, FSB

The ‘Back Side’ of Compartments - Saye Khoo, MD, PhD

Back-terial co-infections - Mohammed Lamorde, FRCP, PhD

Specific Complex Interactions (mechanic presentation) - David Burger, PharmD, PhD

PBPK/PD Modeling and Simulations to Guide Dose Recommendation of Amlodipine after Co-administration with Viekirax or Viekira Pak - Dwaipayan Mukherjee, PhD

Backing up clinical data with modelling - Marco Siccardi, PhD

Effects of Sofosbuvir/Ribavirin Treatment and ITPA Phenotype on Endogenous Purines - Dr. Leah Jimmerson

Rifampin (RIF) Decreases Cabotegravir (CAB) Exposure following Oral Coadministration - Dr. Susan Ford

Increased Tenofovir Diphosphate in Red Blood Cells, but Not Tenofovir in Plasma, with Sofosbuvir and Ribavirin - Dr. Christine MacBrayne

MK-3682, a HCV NS5B Inhibitor with a Broad Spectrum of HCV Genotypic Activity, Demonstrates Potent Antiviral Activity in Genotypes -1,-2, and -3 HCV-Infected Patients - Dr. Nancy Kim

Pharmacokinetics of Darunavir, Ombitasvir, Paritaprevir, Ritonavir, Dasabuvir and Ribavirin in Adults Infected with Hepatitis C Virus (HCV) Genotype (GT) 1 and Human Immunodeficiency Virus Type 1 (HIV-1) - Dr. Jennifer King

Physiologically-based simulation of daclatasvir pharmacokinetics with antiretroviral inducers and inhibitors of cytochrome P450 and drug transporters - Dr. Timothy Eley

Pharmacokinetics of Dolutegravir after Switching to Abacavir/Dolutegravir/Lamivudine from an Efavirenz Based Regimen: A PK Substudy from Striiving - Dr. Jeff de Wet

A Clinically Meaningful Drug-Drug Interaction Observed Between ZepatierTM (Grazoprevir/Elbasvir) and Stribild® HIV Fixed-Dose Combination in Healthy Subjects - Dr. Hwa-Ping Feng

Evaluation of Pan Genotypic HCV NS3/4A Protease Inhibitor GS-9857 as the Object of Transporter and Cytochrome P450-Mediated Drug-Drug Interactions - Dr. Brian Kirby